Thank you for standing by, and welcome to the Compass Pathways First Quarter 2024 Earnings Investor Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star one one on your telephone. If your question has been answered and you'd like to remove yourself from the queue, simply press star one one again. As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Mr. Steve Schultz, Senior Vice President, Investor Relations. Please go ahead, sir. Welcome, all of you, and thank you for joining us today for our first quarter 2024 results conference call. Again, my name is Steve Schultz, Senior Vice President of Investor Relations at Compass Pathways, and today I'm joined by Kabir Nath, our Chief Executive Officer, Dr. Guy Goodwin, our Chief Medical Officer, and Teri Loxam, our Chief Financial Officer. The call is being recorded and will be available on the Compass Pathways investor relations website shortly after the conclusion of the call and will be archived for a period of 30 days. Before we begin, let me remind everyone that during the call today, the team will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. You should not place undue reliance on these forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those risks and uncertainties described under the heading Risk Factors in our annual report on Form 10-K, filed with the U.S. Securities and Exchange Commission and in subsequent filings made by Compass with the SEC. Additionally, these forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements, even if our estimates or assumptions change. I'll now hand the call over to Kabir Nath. Thanks, Steve. Good day, everyone, and thank you for joining us. First, let me report that Compass continues to execute on both of the phase III COMP360 trials in treatment-resistant depression. We're on track to deliver top-line data for the COMP005 single-dose placebo-controlled study in the fourth quarter of this year, and for the COMP006 fixed repeat dose trial in mid-2025. We're also actively working on completing all necessary preclinical and clinical pharmacology studies required for a COMP360 NDA dossier. Also, in this quarter, we announced additional commercial collaborations with leading mental health care providers, designed to inform the development of scalable and cost-effective delivery models for COMP360 psilocybin treatment, if approved for treatment-resistant depression. The most recent announcements of the Journey Clinical and Mindful Health Solutions collaborations add to those we already have in place with Reliant Medical Group, part of Optum Care, Greenbrook TMS, and Hackensack Meridian Health. Each of these partners represents very different but equally important commercial models and settings of care for patients. These collaborations are focused on investigating challenges with the current patient care experience. They will assist Compass and these leading mental health care providers to better understand how COMP360 may best fit into diverse care settings and also enable Compass to develop commercial delivery templates in these different care settings. These collaborations, plus the CPT III tracking code that went into effect in January, are important steps towards preparing the market for a COMP360 psilocybin treatment option, if approved. Let me now hand the call over to Dr. Guy Goodwin for a clinical update. Guy? Thank you, Kabir. It's a pleasure to speak to everyone today and review the positive data generated from the COMP360 phase II clinical study in PTSD. We hope you have the opportunity to review the press release from this morning summarizing the results. This study included three clinical sites in the U.S. and U.K.: the Icahn School of Medicine at Mount Sinai in New York, Sunstone Therapies in Rockville, Maryland, and the Institute of Psychiatry, Psychology and Neuroscience at King's College in London. Now, let me go through some of the specific results we saw with this PTSD study. The study was an open-label, multicenter, phase II exploratory study evaluating COMP360 psilocybin treatment in 22 patients with PTSD resulting from trauma in adulthood. Participants received a single 25 mg dose along with psychological support. Psychological support was provided by a licensed medical professional to ensure patient safety by preparing participants for the treatment session, observing and being present with patients during the session, and supporting them after the session. The majority of patients entered the study with symptoms of PTSD, categorized as severe, with a mean CAPS-5 total score at baseline of 47.5. The CAPS-5 assessment involves a structured interview that provides a PTSD diagnosis aligned with DSM-5 and measures the average severity of 20 symptoms. The average age of participants at the time of screening was 39, and four participants had prior lifetime experience with psilocybin.... veteran status and combat exposure were evaluated, as were measures of the dissociative PTSD subtype. Patients diagnosed with complex PTSD were excluded from study eligibility. The effects of the COMP360 treatment on the CAPS-5 score were assessed at week four and again at week twelve to assess durability of effect. Study observations also included improvement from baseline in mean SDS score, a measure of functional impairment in daily life. Safety over 12 weeks was the primary endpoint of this study, and administration of COMP360 in this patient group was well tolerated, with no serious adverse events observed. We're also pleased to report impressive and sustained rates of response and remission at both week four and week 12. The key findings include administration of COMP360 was well tolerated. There were no treatment-emergent serious adverse events. Treatment-emergent adverse events over 10% included headaches, nausea, crying, and fatigue, predominantly on the day of drug administration. There were two events of suicidal ideation that resolved during the study. The first was a moderate and transient event on administration day in a patient who went on to be a responder. The second event was mild and occurred at week seven in a non-responder. As a reminder, suicidal ideation is a common feature of PTSD, as it is in TRD. We observed an early and durable improvement in symptoms from baseline following a single administration. Improvement in mean CAPS-5 total score from a baseline of 47.5 was observed with a 29.9 point reduction at week four and 29.5 point reduction at week 12. We observed increasing improvement from disability over the 12 weeks. From a mean SDS total score of 22.7 at baseline, there was an 11.7 point reduction at week four and a 14.4 point reduction at week twelve. We also saw high and sustained rates of response and remission relative to baseline, with early onset of symptom improvement. Response, as defined by patients experiencing a greater or equal 15-point improvement on CAPS-5 score, was 81.8% at week four and 77.3% at week 12. Remission, as defined by CAPS-5 total score of less than or equal to 20, was 63.6% at week four and 64.5% at week 12. No patients withdrew from the study, and none returned to antidepressant medication during the trial. Although a small trial with open label design, the results exceeded our expectations and advanced our understanding of potential application of COMP360 in PTSD. We were particularly impressed by the early onset and durability of improvements. We believe that COMP360 could provide a clinically meaningful benefit and substantially improve daily function and quality of life in patients with PTSD. We look forward to submitting the full results of this study for publication and will consider next steps for the program. In addition to TRD, as Kabir mentioned, we are on track for the primary six-week endpoint in COMP005 during the fourth quarter of this year. We are seeing improvements from the actions we took to facilitate the retrieval of medical records, which created a bottleneck earlier in the year. We also remain on track for COMP006 for the primary six-week endpoint mid-next year. We are excited by the profile that's emerging for COMP360 across both TRD and PTSD and the potential benefit for patients. We look forward to our phase III results later this year and next year, and continuing to progress the broader COMP360 program. Let me now hand the call to Teri for our financial review. Thanks, Guy. I'll now step through the Q1 financial results. Cash used in operations in the first quarter was $20.8 million, within the guidance range we provided of $17 million-$23 million, and which assumes that 2022 R&D tax credit would be received in the first quarter. I'm pleased to confirm that HMRC paid our 2022 claim of approximately $15 million in full in the first quarter. Regarding second quarter 2024 financial guidance, we expect net cash used in operations to be between $32 million and $38 million. Turning to full-year financial guidance, we expect cash used in operations to be between $110 million and $130 million. Compass continues to maintain a strong financial position, with cash and cash equivalents of $262.9 million at March 31st, 2024. This compares with $220.2 million at December 31st, 2023. The increase in cash in the first quarter is due to proceeds received through the ATM and exercise of warrants from our August 2023 PIPE. Long-term debt under Hercules loan facility was $29.1 million at the end of the first quarter. With the cash increase in the first quarter, we now expect our cash runway to fund operations into 2026. We will continue to manage our cash carefully to continue advancing our pivotal program and to achieve important milestones that we believe will create value for our shareholders. Thank you, and I'll now turn the call back to Kabir. ...Thank you, Teri. With these strong PTSD data, we're now working to schedule a meeting with the FDA and align on potential next steps. While TRD is our lead indication for COMP360, we see logical expansion into PTSD, given the similarities in patient profiles and the potential commercial synergies. We're looking forward to disclosing our top-line data for our phase III program later this year. This will be a key milestone for Compass, and given our leadership, a significant event for the field of psychedelic science. We also continue to make great progress with the network of interventional psychiatry centers and mental health care providers who can administer COMP360 treatment, if approved. Our expanding collaborations are indications of interest from providers, and we'll continue to develop commercial models that enable rapid, scalable, broad, and equitable access to COMP360. I also want to welcome Dr. Mike Gold to the Compass team as our new Chief Research and Development Officer, effective May 20th. Mike brings more than 25 years of experience across all aspects of drug development in neuroscience, with extensive therapeutic experience in neurological and psychiatric disorders, including depression. Mike will work with Guy to continue to develop COMP360 in TRD and other indications, and to explore and advance other potential pipeline opportunities. I want to thank Trevor Mill, Compass' current Chief Development Officer, for his dedication and expertise in guiding the development of our COMP360 program over the past several years and exploring additional early pipeline opportunities. Trevor will leave after a transition period with Mike, and we wish him all the best in his future endeavors. This is an exciting year for Compass Pathways, and we look forward to updating you on our continued progress. Thank you again for your participation on today's call. We'll now turn to Q&A, so I'll hand it back to the operator. Certainly. One moment for our first question. Our first question comes from the line of Vikram Purohit from Morgan Stanley. Your question, please? Hi, good morning. Thank you for taking our questions. So we had two on PTSD. So first, could you just frame for us, in terms of real-world experience and real-world benefit, what the CAPS-5 and SDS, SDS scores that you reported this morning, how to contextualize those in terms of, the benefits that patients may observe? And then also, another company in the space recently received notice that the FDA is going to be scheduling an Ad Comm meeting for early June to review their, application for their MDMA-assisted therapy for PTSD. Just wanted to see what your thoughts were there on, potential implications for your program and the space more broadly. Thank you. Thanks, Vikram. It's Kabir. As we start, just want to make sure you can hear us clearly. Yes. Okay, great. So I'll hand to Guy to take the first question, and maybe the second, and I might add on that as well. So, So, Guy? Yeah. So I think the way to think about these results is that they reflect a real near return to normality for a significant number of patients in the study. I mean, these rating scales are not terribly familiar, so we're all getting to understand them as we go along. But basically, they reflect the lowest scores that we see reflect essentially complete recovery. The average, of course, is not that, and there's a range of outcomes, but we emphasize, I think, that these very high rates of remission, as defined by a minimum score, are high, and we think that's important also that they're sustained. I think I would also draw your attention to the SDS scores. They reflect a measure of disability that is used across trials, and so that allows you to look at the impact of other treatments in other conditions, as well as potentially in PTSD. That, again, reflects the numbers that we show, reflects substantial return of function for patients, which is as important as a reduction in symptoms, of course. The second question about Lykos? Yeah, I mean, let me take that. And so, I mean, I think first, no surprise, this is, as they've said, the first submission in PTSD for more than a quarter of a century, number one. Second, it is currently a Schedule I drug. So in that sense, no surprise that there is going to be an Ad Comm. And I would just say we wish them well, and obviously we, like many other people, will be observing very closely how the FDA poses a number of the key questions around that application. Got it. Thank you. Thank you. One moment for our next question. Our next question comes from the line of Ritu Baral from TD Cowen. Your question, please? Good morning, guys. Thanks for taking the question. Quick thing on potential positioning versus the Lykos compound and MDMA-assisted psychotherapy. Kabir and Guy, could you walk us through sort of the nature of the psychological support that you provide? Was there any aspect of exposure therapy, which from my understanding, is sort of the basis for the psychological support provided by Lykos? If you could talk to, like, the amount and then the nature. And then I have a follow-up. Thank you. Thanks. I'll hand to Guy in a moment, but, I mean, the headline, Ritu, is this is no different from what we're doing in TRD. But Guy, please. Yes, thanks, Ritu. In fact, we have quite a detailed follow-up questionnaire, which we'll be publishing the results from in due course. And what that suggests is that essentially patients do not really have the same kind of exposure experience. There's a little bit of that, but mainly there is really just a change in the way people contextualize their memory and their experience. And that seems to be essentially driven by this inward journey that everyone has heard about in relation to psilocybin. So patients are prepared in the same way as we prepare the TRD group, as you've heard. There's no exposure-specific exposure exercises as would occur with a conventional psychotherapy. And patients indeed remark who have had previous psychotherapy, in contrast to that, that they feel that they are, in a sense, doing their own work, that they are leading themselves, and they're not being driven by an external interactive force, which would be the therapist in conventional psychotherapy. So it's a very interesting contrast. The preparation, of course, in terms of hours and so on, and subsequent integration is relatively short. And we think that the efficacy is remarkable, given that it's sustained after 12 weeks. Very helpful. And then can you just talk about some of the exclusion criteria as it relates to suicidality? Were you able to exclude patients with a history of suicidality? Was there anything unique in the history of those two patients that did experience suicidality? Yeah, I mean, this is a group, even though this was not complex PTSD, because this was really a first study, we wanted to be careful not to recruit too vulnerable patients than the severe, probably the complex PTSD group would be that. So this is a single trauma, which also simplifies the measure of outcome. But these patients also show significant history of suicidality. So 70% of them express, had expressed in their lifetimes a wish to be dead, and as many as 30% of them had expressed active suicidal ideation with specific plans and intent. So this is a group that had lifetime suicidality as a feature of the illness. The particular group were obviously recruited at a stage where they were not suicidal, and therefore, we are therefore, what we're seeing is relatively sub-threshold effect. There were no serious adverse events. Of course, there were no attempted suicides or suicides, which unfortunately is a risk in this condition. Got it. If I could have just one quick follow-up, and a follow-up to the first question. Kabir, you left us hanging when you said you would have some key questions that you'd love to have answered by the Lykos Ad Comm. Can you elaborate a little further on that? What questions do you have that you hope the Ad C omm addresses? So the one, and again, it's up to them to comment on how they think that will go. But clearly, and as we've said this before, the Lykos protocol is therapy. And in fact, you know, your question itself proves that, for the fact that there is a significant therapeutic component. And that clearly is something that we'll be interested to see how the FDA understands that, views that, and ultimately, if they're successful, how that will be reflected in labeling and so on. I think that's probably the key question. As well as, you know, clearly the overall assessment of benefit risk for what is, you know, generally categorized as a psychedelic. But again, we could get into arcane arguments about that. But I think, again, how the FDA approaches the overall benefit risk, how can... Great. Thank you so much. Thank you. One moment for our next question. Our next question comes from the line of Charles Duncan from Cantor. Your question, please. Hey, good morning, Kabir and team. Congrats on the progress. I had a question on PTSD and then one on TRD. On the PTSD data seems fairly robust. So I guess, you know, at the risk of jumping the gun, I know that you are seeking FDA input, but could you imagine a relatively capital-efficient phase III program, maybe including one or two studies, both with less than, say, roughly 90 patients, given the, you know, call it, magnitude of change that you're seeing in CAPS-5? So, Charles, you're not going to trick me into designing a phase III study on this call. Suffice to say, obviously, you know, we are encouraged by this data. As I said, we clearly are working on plans and development plans. We will need to take a robust outline of that to the agency, together with this data, to have that discussion. What that number of trials is, the sizing and so on, is still very much to be determined, but you have my assurance. We will be doing it appropriately, trading off robust evidence and capital efficiency. You know, both of those will be goals in whatever design we put forward. Appreciate that. Confident in it. Moving on to TRD, another question you're probably not going to be interested in answering, but I'll ask it anyway. Can you provide any color on the number of patients or, or at least the kind of pacing of patients into part B and even part C, in terms of retreatment on a blinded basis in part B and then open label? Thanks. You were right. The answer is no, I'm not going to give specifics, except to say, as we've said, we clearly have patients in both parts. But also importantly, as we've also said, that the dropouts are running significantly lower than what we had potentially anticipated in the trial, which I think is, again, a good sign. ... Got it. Thanks for taking the questions. Thanks, [Rob]. Thank you. One moment for our next question. Our next question comes from the line of Patrick Trucchio from HC Wainwright. Your question, please. Thanks. Good morning, and congrats on this very positive outcome in PTSD. I'm wondering if you can talk a little bit about the trial design for the phase II study in PTSD relative to the FDA guidance for psychedelic drug development, and, you know, discuss any of the learnings that have emerged that could have an impact or inform the potential phase III trial on PTSD. And then secondly, I'm wondering, regarding the pivotal phase one trial in TRD, with top-line data expected in the fourth quarter, can you frame for us what data you would expect to include in that top-line release? How we should think about the outcome from this study relative to both the phase II-B trial and TRD, as well as possible read-through to the outcome from the pivotal trial two in TRD, where the top-line data is expected mid-2025. Thanks, Patrick. So, I'll hand to Guy in a moment, but I guess just the first thing to say, a reminder, this phase II was an open label, 22 patient study. But let me hand to Guy to say anything around the FDA guidance that will inform how we think about further design. Yeah, I mean, the FDA have obviously expressed an interest in seeing comparisons with another treatment. That can be placebo, or it can be another dose of the active treatment or even an active placebo. So they've left really quite a wide range of options for anyone developing a drug in this space, and we'll take that into account when we think carefully about how we design our phase II and indeed phase III program for PTSD. I don't think there are tremendous differences between TRD and PTSD from what we've seen. But of course, there'll be the advantage of a shared safety database with TRD. There's no reason not to read across to the PTSD indication. On your second question, Patrick, again, we have not guided to what exactly we'll be in a position to release with top line. As you're aware, you know, this part B runs to 26 weeks blinded, so we're going to have to be sensitive around that in terms of that. And look, you know, we have powered and designed this study for success, clearly, and we believe that any significant result will be very positive and further evidence of the potential for COMP360 in TRD. I don't know, Guy, in terms of any read-through from COMP005 to COMP 006, if you have any comment you want to make. Not really. I mean, I think we see COMP006, I think as we've said before, Patrick, we see COMP006 as being particularly informative from a clinical perspective rather than simply a regulatory one. You know, in that it will, with any luck, help us to understand the number of treatments that are probably required in ordinary practice, potentially going forward, which is essential to the commercial model and to the acceptability to clinicians and patients as well. Right. That, that's helpful. And if I could, just on these commercial collaborations, following another announced today. I'm wondering if, do you have an estimate or an expectation for the proportion of the TRD population you may be able to reach at the time of the potential launch based on these commercial collaborations? Or how significant should we think about these collaborations in preparation, you know, for possible rollout of COMP360 and TRD? Thanks, Patrick. It's a great question. So to be clear, these collaborations are really learning exercises. They are examples of different settings of care, and while some, like for instance, Greenbrook TMS, we would expect potentially to be, you know, numerically a significant contributor to commercial rollout. Others, this is all more about building templates, understanding delivery models that we will then need to apply to a wide range of other healthcare settings. So what I would say at this stage is you could think of them really as, as this learning experience, really to deepen our understanding of the potential, to deepen our understanding of these different areas. But assuming we're fortunate enough to file, you can imagine that the year pre-launch is when we will be really scaling those templates across a number of those different settings with different healthcare providers. Great. Thanks so much. Thank you. One moment for our next question. Our next question comes from the line of Tom Shrader from BTIG. Your question, please. Good morning. Thanks for taking the question. It's a remedial one on PTSD. So patients with your baseline score, what level of impairment do they have? What level of medical care are they using? And would a group like this, at some level, support the same price as your TRD patients? Thanks. So they'd be classified as severe, and one of the criteria for the way in which one scores the CAPS-5 is that it would merit intervention or require intervention when people score two or three, particularly on the scales that are used, for each item or symptom. It's a complicated scale, I'm afraid, so it needs a little... We will be unpacking it a little more in the future. But that gives you some idea that these are a group who would need treatment. They're not a group who are sort of mild and coming in for the experience. Yeah. Any background on how much they're hospitalized? We don't have all of the data on these patients yet. This is very much top line, so when we get all the tables in, we'll be able to give you that, that color. Roughly half were on something, an SSRI- Yeah. antidepressant or something. I think all have received previous treatment of some kind. Sorry, if that was the question, that, that's the answer. That included psychotherapy as well as drug treatment, and about half were actively still on site, on, on drugs, which we then discontinued. And Tom, to your second question, I would say we still have a lot of work to do to actually finalize the profile for TRD, let alone PTSD. So again, you know, we couldn't, genuinely couldn't comment on how many administrations we would see for PTSD, what durability we might expect to see in a, in a subsequent trial and so on. So on a sleep parameter, to comment on how these would relate to each other commercially. Perfect. Thank you. Thank you. One moment for our next question. Our next question comes from the line of Sumant Kulkarni from Canaccord Genuity. Your question please. Good morning and afternoon. Thanks for taking my questions, and nice to see the PTSD data. I have two. So first, on COMP360, how can the company optimally mitigate the risk associated with suicidal ideation in trials, given both TRD and PTSD have high background rates of this type of event in patients to start with? And second, it's very nice to see Dr. Michael Gold on board. Given Michael's extensive experience with multi-asset companies, how do you think the strategy of Compass might evolve going forward in time, in terms of the types of compounds that Compass might be looking at? Well, thanks, Sumant. I think the standard answer to this is really that we don't recruit patients who are actively suicidal, because it really doesn't seem ethical to randomize them to no treatment or low treatment. And I think everyone takes that approach. Ultimately, it's impossible to completely exclude the existence of suicidality in these sorts of patient populations. Otherwise, you're not studying a truly generalizable sample. But, you know, we insist that our preparation and the support during the administration optimizes the preparedness of patients. And we think for that reason, we're seeing these relatively minor changes in the in a rating scale. Bear in mind that we had no attempted suicides or suicides in any of our studies, and what we're seeing and describing here are changes on a scale which is sub-threshold for actual events that you would classify as clinically serious, particularly in this study. Sumant, to your question, yes, certainly. I think first, we've always said that we need to establish credibility with COMP360. I believe with our progress with TRD and what we've announced today with PTSD, we're well on the way to doing that. We do have discovery assets, some of which we could be in a position to advance into first-in-human in the relatively short timeframe. But I think having established ourselves as a credible developer, you know, late-stage developer of drugs, it absolutely is part of our thoughtful strategy to how we might expand into other assets over time. But recognizing, again, you know, that's, that's not a given. We have to demonstrate credibility and success with our lead assets, and I think we're well on the way to doing that. Got it. Thanks. Thank you. And as a reminder, if you do have a question at this time, please press star one, one. And our next question comes from the line of Elemer Piros from Rodman. Your question please. Yes, good morning. Maybe a question to Guy. Guy, I'm looking at the PTSD results with MDMA from the phase III trial, and it appears that it takes about 12 weeks to reach maximal benefit with MDMA plus therapy. How does that compare to what you observed with a single dose of COMP360? Well, our CAPS-5 number is taken at four weeks. It's the first measure we take because it's a four-week measure, and of course, that shows the full effect at four weeks, and it's sustained out at 12 weeks using the same measure. So that's what we appear to see. We will have an even finer grain evidence for early, very speedy onset from other measures that we took from patients, but we don't yet have available to show you, but we will have them in due course. So do you believe that the results with MDMA are probably due to the second dose, the third dose amplifying the effect and, you know, with the end results being about the same reduction in CAPS-5 as what you see? Yeah, that's what we all see. Yeah. Yeah. Thank you. Thank you very much. Thank you. Thank you. This does conclude the question and answer session of today's program. I'd like to hand the program back to management for any further remarks. So just to say thanks to all for your participation. As I say, I think as we've heard also during the questions, we're very encouraged by this robust signal we've seen in PTSD. We are working to look at what our future program might be. We continue to execute on the timelines we established in February for COMP005 and COMP006 in TRD. And I think therefore, we are looking forward to exciting news later in the year. So thanks everyone for your participation. Thanks for your support. I wish everyone a very good rest of the day. Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.